Allspring Global Investments Holdings LLC Purchases Shares of 1,814 Harrow Health, Inc. (NASDAQ:HROW)

Allspring Global Investments Holdings LLC acquired a new position in shares of Harrow Health, Inc. (NASDAQ:HROWFree Report) in the 3rd quarter, HoldingsChannel reports. The firm acquired 1,814 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds also recently modified their holdings of the company. Metropolitan Life Insurance Co NY acquired a new stake in Harrow Health in the second quarter worth about $27,000. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Harrow Health during the fourth quarter worth $31,000. Tower Research Capital LLC TRC grew its stake in shares of Harrow Health by 530.7% during the third quarter. Tower Research Capital LLC TRC now owns 2,756 shares of the company’s stock worth $33,000 after purchasing an additional 2,319 shares during the period. Ameritas Investment Partners Inc. acquired a new stake in shares of Harrow Health during the second quarter worth $41,000. Finally, Captrust Financial Advisors acquired a new stake in shares of Harrow Health during the second quarter worth $51,000. Institutional investors and hedge funds own 75.75% of the company’s stock.

Insider Buying and Selling

In related news, CEO Mark L. Baum bought 7,500 shares of Harrow Health stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average cost of $8.11 per share, with a total value of $60,825.00. Following the purchase, the chief executive officer now owns 2,022,961 shares in the company, valued at $16,406,213.71. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 13.60% of the company’s stock.

Analyst Ratings Changes

Separately, TheStreet cut Harrow Health from a “c-” rating to a “d+” rating in a research note on Tuesday, December 12th.

View Our Latest Analysis on HROW

Harrow Health Stock Up 7.0 %

Shares of Harrow Health stock opened at $9.95 on Wednesday. Harrow Health, Inc. has a 1 year low of $7.60 and a 1 year high of $28.25. The company has a debt-to-equity ratio of 2.42, a current ratio of 5.80 and a quick ratio of 5.33. The company has a market capitalization of $349.44 million, a P/E ratio of -22.11 and a beta of 0.44. The business has a 50-day moving average of $10.03 and a two-hundred day moving average of $13.29.

Harrow Health (NASDAQ:HROWGet Free Report) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The company had revenue of $34.27 million during the quarter, compared to the consensus estimate of $37.58 million. Harrow Health had a negative net margin of 12.44% and a negative return on equity of 6.55%. The business’s quarterly revenue was up 50.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) EPS. As a group, equities analysts predict that Harrow Health, Inc. will post -0.43 EPS for the current year.

Harrow Health Company Profile

(Free Report)

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Recommended Stories

Want to see what other hedge funds are holding HROW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harrow Health, Inc. (NASDAQ:HROWFree Report).

Institutional Ownership by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.